NEWTON, Mass. & SANTA CLARA, Calif.--(BUSINESS WIRE)--Clinical Data Inc. (NASDAQ:CLDA) and Affymetrix Inc. (NASDAQ:AFFX) today announced a marketing agreement for a new drug metabolism service using the Affymetrix Drug Metabolizing Enzymes and Transporter (DMET) Early Access solution. Cogenics and Epidauros Biotechnologie AG, both subsidiaries of Clinical Data Inc., will offer the DMET services on a global basis, with limited exclusivity in Europe. Affymetrix (DMET) Early Access solution is currently the world’s most comprehensive method for assaying the genetics of drug metabolism. The service will enable pharmaceutical customers to generate comprehensive genetic profiles of a patient’s metabolic status to gain a better understanding of pharmacokinetic drug response. In a separate release issued today, Affymetrix announced the availability of its DMET Early Access Solution.
